Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Current Opinion in Investigational Drugs

Volumn 6, Issue 3, 2005, Pages 269-274

  Singh, Rashmi K ^a   Barker, Stewart ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

arrestin; Angiotensin receptor; Angiotensin converting enzyme; Atherosclerosis; Hypertension; Restenosis

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN II DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; BRADYKININ; BZ 18; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; G PROTEIN COUPLED RECEPTOR; IRBESARTAN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; OLMESARTAN; PERINDOPRIL; PERINDOPRILAT; PLACEBO; SARCOSINE; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 12; VALSARTAN;

ALDOSTERONE RELEASE; ANGIONEUROTIC EDEMA; ARTERY CONSTRICTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA HALF LIFE; RESTENOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 15844413783     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Kohlman-Trigoboff D: Hypertension management in patients with vascular disease. J Vasc Nurs (2004) 22(2):53-56.
2. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom S: Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2000-BHS IV J Hum Hypertens (2004) 18(3):139-185.
3. Re RN: Tissue renin angiotensin systems. Med Clin North Am (2004) 88(1):19-38.
4. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev (2000) 52(1):11-34.
5. Walther T, Menrad A, Orzechowski H-D, Siemeister G, Paul M, Schimer M: Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J (2003) 17(14):2061-2067.
6. Garthwaite SM, McMahon EG: The evolution of aldosterone antagonists Mol Cell Endocrinol (2004) 217(1-2):27-31.
7. Rodgers JE, Patterson JH: Angiotensin II-receptor blockers: Clinical relevance and therapeutic role. Am J Health-Syst Pham (2001) 58(8):671-683.
8. Department of Defence Pharmacy: Angiotensin Converting Enzyme (ACE) Inhibitor Class Review. Department of Defence Pharmacy & Therapeutic Committee Meeting (2000).
9. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V: Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res (2003) 93(2):148-154.
10. Weber MA: The angiotensin II receptor blockers: Opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med (2002) 3(4):183-191.
11. Manohar P, Pina IL: Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure. Mayo Clin Proc (2003) 78(3):334-338.
12. Weber MA, Bakris GL, Neutel JM, Davidai G, Giles TD: Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (2003) 5(5):322-329.
13. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Galzer R: Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: Results from the Valsartan Heart Failure Trial. Circulation (2003) 108 11):1306-1309.
14. Sica DA, Black HR: Angioedema in heart failure: Occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy. Congest Heart Fail (2002) 8(6):334-341.
15. Latini R, Masson S, Staszewsky L, Maggioni AP: Valsartan for the treatment of heart failure. Expert Opin Pharmacother (2004) 5(1):181-193.
16. Sica DA, Elliot WJ: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: Theory and practice. J Clin Hypertens (2001) 3(6):383-387.
17. Tan LB, Williams SG, Goldspink DF: From CONSENSUS to CHARM - how do ACEI and ARB produce clinical benefits in CHF? Int J Cardiol (2004) 94(2-3):137-141.
18. O'Loughlin DC, Chu VL, Singh D: Perindopril. Heart Dis (2000) 2(6):446-455.
19. Doggrell SA, Wanstall JC: Vascular chymase: Pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res (2004) 61(4):653-662.
20. 1 receptors. Br J Pharmacol (1999) 126(4):1057-1065.
21. 1 receptor antagonists. Trends Pharmacol Sci (2000) 21(10):376-381.
22. Ostergren J: Candesartan for the treatment of hypertension and heart failure. Expert Opin Pharmacother (2004) 5(7):1589-1597.
23. 1 receptor interaction: Further support by binding studies at low temperature. Biochem Pharmacol (2003) 65(8):1339-1341.
24. 1 receptor interaction: An hypothesis defended but not tested. Biochem Pharmacol (2004) 67(3):397-399.
25. Takezako T, Gogonea C, Saad Y, Noda K, Kamik SS: "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. J Biol Chem (2004) 279 15):15248-15257.
26. 1 receptor in complex with angiotensin II independently validated by site-directed mutagenesis data. Biochem Biophys Res Commun (2001) 286(5):1204-1211.
27. 1 receptor play a relevant role in agonist binding and activity. Regul Pept (2002) 106(1-3):33-38.
28. Klabunde T, Hessler G: Drug design strategies for targeting G-protein-coupled receptors. Chembiochem (2002) 3 10):928-944.
29. Burnier M, Maillard M: Angiotensin II receptor antagonists: Where do we stand? IDrugs (2000) 3(3):304-309.
30. 1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension (2004) 43(3):686-691.
31. 1 antagonists: Stereoelectronic requirements for antihypertensive efficacy. J Pharm Biomed Anal (2003) 31 5):833-844.
32. Barker S: Mechanism of action of peptide hormones. In: Molecular Endocrinology: Genetic Analysis of Hormones and their Receptors. Rumsby G, Farrow SM (Eds), Bios Scientific Publishers Ltd, Oxford, UK (1997) 3:47-71.
33. Luttrell LM, Lefkowitz RJ: The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci (2002) 115(Pt 3):455-465.
34. Luttrell LM: 'Location, location, location': Activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinol (2003) 30(2):117-126.
35. Wei H, Ahn S, Shenoy SK, Kamik SS, Hunyady L, Luttrell LM, Lefkowitz RJ: Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA (2003) 100(19):10782-10787.
36. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ: Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 279 34):35518-35525.
37. Wagenaar LJ, van Boven AJ, van der Wal AC, Amoroso G, Tio RA, van der Loos CM, Becker AE, van Gilst WH: Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries. Cardiovasc Res (2003) 59(4):980-987.
38. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, Komune S: Effects of the angiotensin-1 converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol (2004) 130 10):567-573.
39. Dickstein K: What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J (2003) 145(5):754-757.
40. Sica DA: ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM trials). Congest Heart Fail (2004) 10 3):160-164.
41. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 40(8):1414-1421.
42. Maggioni AP, Latini R: RAAS inhibitors in the cardiovascular continuum: What is still missing? Cardiovasc Drugs Ther (2004) 18(4):311-320.
43. Swedberg K, McMurray JJV: Angiotensin receptor blockers and heart failure: Still CHARMing after VALIANT? Eur Heart J (2004) 25 5):357-358.